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To exert beneficial effects for the host, for example, improving the intestinal microflora, a probiotic must reach the intestine as a viable strain. These
properties must be demonstrated by in vitro as well as in vivo methods. However, only a few well-designed human clinical studies have shown these
properties. Lactobacillus johnsonii La1 has been shown to give many beneficial effects for the host, but it is unclear whether a viable strain of L. john-
sonii La1 has the effect of improving host intestinal microflora. In the present study, a randomised double-blind placebo-controlled cross-over trial was
conducted to elucidate the effect of L. johnsonii La1 on human intestinal microflora. Twenty-two young healthy Japanese women were randomly divided
into two groups, and either received fermented milk with L. johnsonii La1 or a fermented milk without L. johnsonii La1 (placebo) daily for 21 d. Con-
sumption of the fermented milk: (a) increased total Bifidobacterium and Lactobacillus, and decreased lecithinase-positive Clostridium in the faeces; (b)
increased the faecal lactic acid concentrations; (c) decreased the faecal pH; (d) increased the defecation frequency. These changes were stronger than
those observed with the placebo. L. johnsonii La1 was identified in all subjects only after the consumption of the fermented milk. These results suggest
that L. johnsonii La1 can contribute to improve intestinal microflora with probiotic properties.
Double-blind placebo-controlled trial: Lactobacillus johnsonii La1: Probiotics: Intestinal microflora: Viable strains
In order to protect against invasion of pathogens and maintain
body homeostasis, man has developed body defence systems.
Since the intestine is continuously exposed to potential patho-
gens (partially taken up with the diet), which can invade the
host, natural defence systems have been developed in the
intestine, such as mucosal mucins and lysozyme. The intesti-
nal microflora also plays an important role to contribute to
the overall defence system in the intestine. It is known that
germ-free animals have a higher incidence of infection than
conventional animals (Collins & Carter, 1978), and intestinal
intra-epithelial lymphocytes of axenic animals increase after
bacterial colonisation (Imaoka et al. 1996). The intestinal
microflora is significantly related to the health and diseases
of the host (Benner et al. 1981; Sudo et al. 1997; Cebra
et al. 1998); in particular, Bifidobacterium and Lactobacillus
contribute to beneficial defensive effects of the host. They
exert antimicrobial effects against pathogens by releasing anti-
microbial substances (Corthier et al. 1985; Gopal et al. 2001)
or prevent adhesion of pathogenic bacteria onto epithelial cells
(Chan et al. 1985). They activate natural killer cells (Haller
et al. 2000a; Nagao et al. 2000), enhance IgA synthesis
(Fukushima et al. 1998; Ibnou-Zekri et al. 2003), modulate
cytokine production (Marin et al. 1997; Haller et al. 2000b)
and contribute to the maintenance of body homeostasis
(Hata et al. 1996; Kiessling et al. 2002). They also aid nutri-
tional absorption (McDonough et al. 1983) and vitamin syn-
thesis (Gibson & Roberfroid, 1995). On the other hand,
harmful bacteria such as Clostridium perfringens are associ-
ated with various diseases and inflammatory responses (Del-
neste et al. 1998; Matzinger, 1998; Haller et al. 2000b).
Considering these facts, it is quite useful to improve the intes-
tinal microflora; that is, to increase the indigenous beneficial
bacteria and, by this, decrease harmful bacteria, for both
host defence and nutritional benefits.
Recently, probiotic products containing certain strains of
Bifidobacterium and Lactobacillus (Fuller, 1989; Lee & Sal-
minen, 1995), which are normal inhabitants in the human
adult gastrointestinal tract (GIT; Dubos et al. 1965; Lidbeck
& Nord, 1993), have been shown to give beneficial effects
on the host by improving the intestinal microflora. However,
most studies, which show the impact of probiotics on the
intestinal microflora, were performed without placebo or
were non-blinded. Only a few studies show that either the
strain(s) in the product or the product components have an
effect to improve the intestinal microflora by means of
double-blind placebo-controlled design.
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Lactobacillus johnsonii La1 (NCC533; Nestle´ Culture
Collection, Lausanne, Switzerland), which formerly belonged
to the L. acidophilus group (Johnson et al. 1980; Fujisawa
et al. 1992), was selected as a candidate of probiotics under
the hypothesis that bacteria with adherence properties on intes-
tinal epithelial cells (IEC) would more efficiently strengthen the
host defence system than non-adherent strains. Since the intes-
tinal epithelium is a target for pathogenic encounter and start
site of infection, some well-adherent probiotic strains have
the potential to prevent infection by competitive exclusion of
pathogens in vitro. In addition, the modulation of the host
immune system through the induction of strain-specific signals
by L. johnsonii La1 to the IEC has been shown using the IEC–
peripheral blood mononuclear cells co-culture model. It was
also shown that L. johnsonii La1 had stronger adherence on
the human Caco-2 and HT-29 cells than other Lactobacillus
strains in vitro (Johnson et al. 1980; Bernet et al. 1994; Gopal
et al. 2001). Finally L. johnsonii La1 was also shown to contrib-
ute to the reinforcement of the host defence systems. Antimicro-
bial activities against pathogens (Bernet-Camard et al. 1997;
Blum et al. 1999), anti-pylori effects (Tuomola et al. 1999;
Felley et al. 2001) and activation of both natural and specific
immunity by the fermented milk containing L. johnsonii La1
have been reported (Link-Amster et al. 1994; Marteau et al.
1997; Donnet-Huges et al. 1999; Michetti et al. 1999). How-
ever, the effect of L. johnsonii La1 on the intestinal microflora
composition remains unclear.
The following criteria for probiotics have been suggested (Lee
& Salminen, 1995; Schiffrin et al. 1995; Salminen et al. 1996):
human origin; safe for consumption; adhesive property onto
human intestinal epithelium; survival in the GIT, transient colo-
nisation of the intestine; production of antimicrobial substances;
antagonism against pathogenic bacteria; demonstrated ben-
eficial effects on human health. Especially, survival ability in
the GIT is considered to be of great importance for exerting pro-
biotic effects on the heart. Although L. johnsonii La1 is highly
resistant against gastric juice and bile acid in vitro (Prasad
et al. 1998), this does not mimic exactly the conditions in situ.
In the present study, a randomised double-blind placebo-
controlled cross-over trial was conducted to elucidate the
strain-specific effect of L. johnsonii La1 on the intestinal
microflora in young healthy Japanese women. We also deter-
mined the ability of L. johnsonii La1 to adhere to Caco-2 cells
and survive under GIT conditions in vitro.
Material and methods
In vitro test
Adhesion test. L. johnsonii La1 and L. acidophilus La3, La4,
La5, La7, La10 and La18 (Nestle´ Culture Collection) were
used. L. johnsonii La1 and L. acidophilus La5 and La7 are
able to colonise gnotobiotic mice associated with human
faecal flora, while other strains (L. acidophilus La3; Benner
et al. 1981; Gibson & Roberfriod, 1995; Haller et al. 2000a)
do not (, unpublished results). The adherence of bacteria onto
Caco-2 cells was examined as described previously (Bernet
et al. 1994). Briefly, Caco-2 cell monolayers were prepared
on glass coverslips placed in six-well tissue culture plates
(Corning Glass Works, Corning, NY, USA). Cells were
seeded at 1·4 £ 104 cells per cm2. Cells were maintained at
378C in a CO2–air atmosphere (10:90, v/v). Lactobacilli
(1ml; 4 £ 108 bacteria/ml) in the bacterial supernatant fraction
or fresh de Man, Rogosa and Sharpe (MRS) broth (Becton,
Dickinson and Company, Franklin Lakes, NJ, USA) were
added to 1ml of the cell line culture medium. This suspension
(2ml) was added to each well of the tissue culture plate.
Plates were incubated at 378C in CO2–air (10:90, v/v) for 1 h.
After the incubation, monolayers were washed with sterile
PBS, fixed with methanol, stained with Gram stain, and exam-
ined with a microscope. Each adhesion assay was conducted in
triplicate over three successive passages of intestinal cells. For
each monolayer on a glass coverslip, the number of adherent
bacteria was evaluated in twenty random microscopic areas.
Two different technicians evaluated adhesions to eliminate bias.
Resistance against simulated gastric juice
L. johnsonii La1, L. reuteri, L. gasseri, L. amylovorus, L. plan-
tarum, Bifidobacterium longum and B. breve (Nestle´ Culture
Collection) were used for in vitro GIT transit tolerance test. To
simulate gastric juice, 0·3% (w/v) pepsin in 0·5% (w/v) sterile
saline at pH 2·0 was prepared and bacteria (1·0ml; 4 £ 108
colony-forming units (cfu)/ml) were suspended into the simu-
lated gastric juice. They were gently mixed and incubated at
378C for 3 h. Samples of 0·1ml were removed 0, 1 and 3 h
after anaerobic incubation and decimal dilution series with
saline were prepared. From an appropriate dilution, 50ml of
samples were plated onto MRS agar media. After anaerobic
incubation at 378C for 48 h, total viable bacteria were counted.
Resistance against bile acid
L. johnsonii La1, L. reuteri, L. gasseri, L. amylovorus, L. plan-
tarum, B. longum and B. breve (1·0ml; 4 £ 108 cfu/ml) were
suspended in 1% inoculum in MRS broth with 0·1% bile
acid (Becton, Dickinson and Company) at 378C for 15 h.
Samples of 0·1ml were removed 0 and 15 h after anaerobic
incubation, and total viable bacteria were counted in the
same manner as described earlier.
Resistance against simulated gastrointestinal tract conditions
L. johnsonii La1 (1ml; 1 £ 107 cfu) was incubated with simu-
lated gastric juice for 30min and 0·1% bile acid for 60min.
Samples of 0·1ml were removed before and after the two-
step incubation, total viable bacteria were counted in the
same manner as described earlier.
Fermented milks
Fermented milks (120 g) contained Streptococcus thermophi-
lus (1 £ 108 cfu) with (test) or without (placebo) L. johnsonii
La1 (1 £ 109 cfu). The composition of both fermented pro-
ducts was as follows: energy, 427 kJ; protein, 4·6 g; lipids,
3·6 g; carbohydrates, 12·9 g; Na, 60mg; Ca, 128mg. Final
pH was below 4·45. Their taste and texture were maximally
adapted at the factory level.
Subjects and study design
Twenty-two young Japanese women from 20 to 22 years of age
were selected as subjects under the declaration of Helsinki.
T. Yamano et al.304
https:/www.cambridge.org/core/terms. https://doi.org/10.1079/BJN20051507
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:18:26, subject to the Cambridge Core terms of use, available at
Informed consent was obtained from all volunteers before
starting the study.
The study was conducted with a double-blind placebo-con-
trolled cross-over design shown in Fig. 1. Subjects were ran-
domly divided into two groups. Following the observation
period without any fermented milks administration for 21 d,
either the test or the placebo-fermented milk was admini-
strated daily for 21 d from day 1 to day 21. All subjects
were requested to stop the consumption of other fermented
milks and diets that might have effects on the intestinal micro-
flora, such as oligosaccharide or dietary fibre. Antibiotics and
cathartics were restricted from being prescribed except at the
time of necessity. Subjects recorded a daily questionnaire on
the number of defecations, diet, prescription and health
remarks during the entire study period.
Faecal flora analysis
Faecal samples were collected at day 220, 27, 0, 11, 22, 50,
61, and 72. Whole faecal samples were stored anaerobically
(Anaero Packw Kenki; Mitsubishi Gas Chemical Company
Inc, Tokyo, Japan) at 48C and provided for faecal flora anal-
ysis within 24 h after defecation. Decimal dilution series of
faecal samples into the saline were prepared. From an appro-
priate dilution, 50ml of samples were plated onto the media
and bacteria were analysed according to the Mitsuoka’s
method (Mitsuoka et al. 1976). Three non-selective media
(Eggerth-Gagnon, blood liver, trypcase sulfite agar media)
and nine selective media (bifidobacteria-selective, enhanced
selectivity, neomycin brilliant green taurocholate, Clostridium
welchii, Clostridia, lactobacilli-selective, triphenyltetrazolium
chloride-acridine, potato dextrose, phenylalcohol–egg yolk
suspension agar media) were used (Table 1). Bacterial species
were identified by colonisation, Gram staining, morphology,
lecithinase reaction, aerobic growth and sporulation. The
ratio of bifidobacteria was calculated by dividing the number
of bifidobacteria by the number of total bacteria.
Identification of L. johnsonii La1
The Lactobacillus colony isolated from lactobacilli-selective
agar media was transferred onto MRS agar media with anti-
biotics phosphomycine (0·8mg/ml; Sigma-Aldrich Co. Ltd,
St Louis, MO, USA), sulfamethoxazole (0·93mg/ml; Wako
Pure Chemical Industries Ltd, Osaka, Japan) and tripetho-
prime (0·05mg/ml; Wako Pure Chemical Industries Ltd),
and anaerobically incubated at 378C for 48 h. Grown bacteria
were washed with 1ml Ringer buffer with 0·5 g L-cysteine
hydrochloride/l (Wako Pure Chemical Industries Ltd) in the
Eppendorf tube and centrifuged at 4000 rpm for 5min. The
supernatant fraction was removed and the pellet was frozen
at 2208C until use. For DNA amplification, 1ml bacterial
pellet, 18ml sterilised water and 5ml proteinase K (10mg/
ml; Amersham Biosciences Corp., Piscataway, NJ, USA)
were mixed and heated at 558C for 30min with Gene Amp
PCR System 9600-R (Perkin Elmer Co., Ltd, Tokyo, Japan).
Heated bacteria (1ml) were added into the tubes premixed
with 1ml 50mM-DNA primer 50(GGTTGGGTGAGAATTG-
CACG)30 (Microsynth GmbH, Balgach, Switzerland), 1·25ml
10mM-deoxynucleotide triphosphate (Amersham Biosciences
Corp.), 0·75ml 50mM-MgCl2 (Amersham Biosciences
Corp.), 1·25ml PCR buffer (Invitrogen Co. Ltd, Tokyo,
Japan) and 8·25ml sterilised water, and incubated at 988C
for 10min, then 1·25ml PCR buffer, 1U plantinum Taq
DNA polymerase (Invitrogen Co. Ltd, Tokyo, Japan) and
11ml sterilised water were added (reaction mix). Following
the initial step of incubation at 948C for 5min, reaction mix
Fig. 1. Study design. A randomised double-blind placebo-controlled cross-over trial was conducted. After 21 d of the non-intake period, either fermented milk con-
taining Lactobacillus johnsonii La1 (1 £ 109 colony-forming units/120 g; test fermented milk) or placebo fermented milk was administered daily for 21 d.
Table 1. Media and conditions used for faecal bacteria identification*
Media Bacteria mainly identified
Incubation contidion
(48 h at 378C)
Non-selective media
EG Anaerobic bacteria Anaerobic
BL Anaerobic bacteria Anaerobic
TS Aerobic bacteria Aerobic
Selective media
BS Bifidobacteria Anaerobic
ES Eubacteria Anaerobic
NBGT Bacteroidaceae Anaerobic
CW Clostridia (lecithinase þ) Anaerobic
Crostridia agar Clostridia (lecithinase 2 ) Anaerobic
LBS Lactobacilli Anaerobic
TATAC Enterococci Aerobic
PEES Staphylococci Aerobic
Potato dextrose agar Yeast Aerobic
EG, Eggerth-Gagnon; BL, blood liver; TS, trypcase sulfite; BS, bifidobacteria-selec-
tive; ES, eubacterium selective; NBGT, neomycine-brilliant green-taurocholate;
CW, Clostridium welchii; LBS, lactobacilli-selective; TATAC, triphenyltetrazolium
chloride-acridine; PEES, phenylalcohol–egg yolk suspension.
*Mitsuoka’s method was used for faecal bacteria identification (Mitsuoka et al.
1976).
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was provided to the amplification reaction for thirty cycles:
denaturation (1min at 958C), annealing (1min at 408C), and
extension (4min at 728C). Amplification products were elec-
trophoresed at 70V for 2 h on 0·8% (w/v) agarose gel with
ethidium bromide (0·3mg /ml) and visualised under UV
illumination.
Faecal organic acid concentrations and pH
Faecal samples were homogenised and centrifuged. Obtained
supernatant fractions were filtrated through chromatodisc
and provided to a SCFA analysis set (Shodex OA; Shouwa-
denkou K.K., Tokyo, Japan). Formic acid, acetic acid, lactic
acid, propionic acid, butyric acid, isobutyric acid, valeric
acid and isovaleric acid were identified.
Faecal pH was measured with a pH meter (Twin; Horiba
Ltd, Kyoto, Japan) by touching the pH meter to faeces
directly.
Statistic analysis
The results are expressed as mean values and standard
deviations.
Data were analysed with software SPSS 11.0 J (SPSS Japan,
Tokyo, Japan). Statistical differences between the test and pla-
cebo groups, and between pre- and post-administration were
examined with the Wilcoxon rank sum test. Statistical differ-
ence on the appearance ratio of faecal bacteria was examined
with the x2 test. The difference between means was considered
significant at P,0·05.
Results
Adhesion ability onto Caco-2 cell in vitro
Fig. 2 shows the adhesion ability of L. johnsonii La1, L. acid-
ophilus La3, La4, La5, La7, La10 and La18 onto Caco-2 cells.
Bacteria with the property of colonisation (L. johnsonii La1, L.
acidophilus La5, La7) showed better adhesion ability onto
Caco-2 cells than bacteria with poor colonisation property
(L. acidophilus La3, La4, La10, La18). L. johnsonii La1
showed the best adhesion ability among the tested bacteria.
Survival ability in the gastrointestinal tract in vitro
Table 2 shows the survival ability of seven strains of Bifidobac-
terium and Lactobacillus in bile acid and the simulated gastric
juice. L. johnsonii La1, L. reuteri, L. amylovorus, L. plantarum,
and B. breve showed survival ability after 15 h incubation in
0·1% bile acids. L. johnsonii La1 showed the best survival abil-
ity against the simulated gastric juice among the test bacteria
and more than 10% of tested L. johnsonii La1 survived after
3 h incubation. In the two-step incubation with simulated gastric
juice for 30min and bile acid for 60min, L. johnsonii La1 was
added at 1 £ 107 cfu and about 4 £ 106 cfu of L. johnsonii La1
showed survival after the incubation.
Intestinal microflora
Table 3 shows the effect of the fermented milks on the intestinal
microflora. During the test period, the average number ofBifido-
bacterium in the faeces increased from 109·3 (SD 100·2) cfu/g (day
0) to 109·4 (SD 100·2) cfu/g (day 11; P,0·05) and 109·7 (SD 100·8)
cfu/g (day 22; P,0·001). The ratio of Bifidobacterium in the
faeces increased from 11·0 (SD 4·3) % (day 0) to 16·6 (SD 4·9)
% (day 11; P,0·005) and 18·0 (SD 7·4) % (day 22; P,0·005)
(Fig. 3). Both the number and the ratio of Bifidobacterium at
day 22 were high compared with those during the placebo
period (P,0·001 and P,0·01, respectively). The average
number of Lactobacillus increased from 105·3 (SD 101·1) cfu/g
(day 0) to 106·5 (SD 101·3) cfu/g (day 11; P,0·001) and 107·1
(SD 100·2) cfu/g (day 22;P,0·001) and theywere high compared
with those during the placebo period (P,0·005 and P,0·001,
respectively). The average number of lecithinase-positive
Clostridium decreased from 105·5 (SD 101·8) cfu/g (day 0) to
103·2 (SD 100·7) cfu/g (day 22; P,0·005) and the number at
day 22 was low compared with that during the placebo period
(P,0·05). The appearance ratio of lecithinase-positive Clostri-
dium decreased from 55% (day 0) to 14% (day 22; P,0·005).
During the placebo period, no significant changes were
observed in either number or the ratio of Bifidobacterium
and Lactobacillus. The average number of lecithinase-positive
Clostridium decreased from 105·3 (SD 100·7) cfu/g (day 0) to
104·3 (SD 101·4) cfu/g (day 14; P,0·05), and the appearance
ratio of lecithinase-positive Clostridium decreased from
55% (day 0) to 14% (day 11; P,0·01) and 23% (day 22;
P,0·05). No significant changes were observed in the count
of total bacteria, Bacteroidaceae or Eubacterium during both
the test and placebo period.
Fig. 2. Adhesion property of lactobacilli. The number of adhering bacteria
onto Caco-2 cell is shown. Lactobacillus johnsonii La1, L. acidophilus La3,
La4, La5, La7, La10 and La18 were used. ( ), Bacteria with a property to
colonise in gnotobiotic mice associated with human faecal flora; ( ), bacteria
with a property to colonise in gnotobiotic mice associated with human faecal
flora; cfu, colony-forming units.
Table 2. Survival ability against bile acid (0·1% for 15 h)
and simulated gastric juice
Gastric juice
Strain Bile acid 1 h 3 h
LactobacillusL. Johnsonii La1 þ þþ þþ
L. reuteri þ þ 2
L. gasseri 2 þ 2
L. amylovorus þ þþ þ
L. plantarum þ þ 2
BifidobacteriumB. longum 2 þ 2
B. breve þ þ 2
þ , More than 1/1000 of the tested bacteria survived; þþ , more than
1/10 of the tested bacteria survived; 2 , no bacterial growth.
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Identification of Lactobacillus johnsonii La1
Fig. 4 shows the changes of L. johnsonii La1 in the faeces. L.
johnsonii La1 was identified in all subjects after the adminis-
tration of the test fermented milk only during the test period
but not at day 0. L. johnsonii La1 was identified neither
during the observation nor placebo period. The number of L.
johnsonii La1 was 106·3 (SD 100·5) cfu/g (day11) and 106·9
(SD 101·4) cfu/g (day 22) during the test period. L. johnsonii
La1 occupied more than 90% of identified total lactobacillus
at day 22. The maximum number of identified L. johnsonii
La1 was 7·5 £ 109 cfu/d. More than the ingested number of
L. johnsonii La1 (1 £ 109 cfu/d) was identified from nine out
of twenty-two subjects. No more L. johnsonii La1 was ident-
ified 4 d after stopping the test fermented milk in all subjects.
Faecal organic acid concentrations and faecal pH
Fig. 5 shows the effect of the fermented milks on faecal lactic
acid and SCFA concentrations. During the test period, lactic
acid increased from 0·031 (SD 0·063) mg/g (day 0) to 0·208
(SD 0·300) mg/g (day 22; P,0·05) on average. Faecal pH
decreased from 7·66 (SD 0·71) (day 0) to 7·17 (SD 0·62) (day
11; P,0·05) and 7·28 (SD 0·61) (day 22; P,0·05) (Fig. 6).
During the placebo period, average lactic acid concentration
increased from 0·025 (SD 0·048) mg/g (day 0) to 0·113 (SD
0·234) mg/g (day 22; P,0·05). No significant changes were
observed on faecal pH during the placebo period.
Defecation frequency
Fig. 7 shows the effect of the fermented milks on defecation
frequency in the subjects with mild constipation at less than
seven defecations/week during the observation period.
Twenty out of twenty-two subjects had mild constipation.
During the test period, defecation frequency in the subjects
with mild constipation increased from 3·8 (SD 1·4) times/
week (days 26 to 0) to 4·9 (SD 1·9) times/week (days 1–7;
P,0·05), to 5·2 (SD 2·8) times/week (days 8–14; P,0·05)
and to 5·7 (SD 2·7) times/week (days 15–21; P,0·05).
During the placebo period, weekly defecation frequency
tended to increase but not significantly. No changes were
observed in two subjects with normal defecation frequency
(more than seven defecations/week during the observation
period) during both the test and placebo periods.
Discussion
Since most of the probiotic strains exert their effects in the
gut, it is very important for the evaluation of probiotics to
show the capability of the given strain to reach the intestine
viable and in high numbers. In the in vitro test, we evaluated
the capability of L. johnsonii La1 to attach onto Caco-2 cells
and survive in simulated GIT conditions. In the adhesion assay
using Caco-2 cells, L. johnsonii La1 showed the strongest
adhesion among seven other bacteria tested. It was recently
shown that the lipoteichoic acid of L. johnsonii La1 and the
gangliotri- and gangliotetra-osylceramides (asialo-GM1) of
Caco-2 cells are involved in the mediation of adhesion (Gran-
ato et al. 1999; Neeser et al. 2000). We also found a positive
correlation between adhesion and colonisation. Bacteria with
ability to colonise in axenic mice associated with human
faecal flora demonstrated a better adhesion property on
Caco-2 cells, suggesting that strains with colonisation proper-
ties in vitro are likely to exert adhesion in situ. Although there
is no direct evidence that probiotic bacteria with adhesion
properties in vitro can also attach to the intestinal epithelium
in vivo, the fact that L. johnsonii La1 has properties to
adhere to other human intestinal cell-lines (HT-29 and HT-
29MTX) suggests a potential of L. johnsonii La1 to colonise
the human intestine (Bernet et al. 1994; Blum et al. 1999).
In the GIT survival test, 0·1% bile acid is likely in human
GIT, pH of human gastric juice is approximately 2·0 and
salt content is not less than 0·5% (w/v). These concentrations
of bile acid and gastric juice were used to simulate human GIT
conditions. L. johnsonii La1 showed survival in both simulated
gastric juice and bile acid. Moreover, L. johnsonii La1 showed
the best survival ability among seven tested bacteria, which
have been reported to have beneficial effects on health
(Mogensen et al. 2002). Although these long-time incubation
tests are often used to evaluate the potential of probiotic
Fig. 3. Effect of fermented milk on faecal Bifidobacterium ratio. Data are
expressed as mean values (n 22), with standard deviations represented by
vertical bars. * The ratio of Bifidobacterium in the faeces was significantly
increased compared with day 0 (P,0·005). † The ratio of Bifidobacterium at
day 22 was significantly higher compared with that during the placebo period
(P,0·01).
Fig. 4. Effect of the fermented milks on faecal total Lactobacillus ( ) and
Lactobacillus johnsonii La1 ( ). Data are expressed as mean values (n 20),
with standard deviations represented by vertical bars. L. johnsonii La1 was
identified neither during the observation nor placebo period. * The number of
L. johnsonii La1 was significantly higher during the test period compared with
that during the placebo period (P,0·001). cfu, Colony-forming units.
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strains (Goldin et al. 1992; Charteris et al. 1998; Prasad et al.
1998), these situations probably do not occur in the body, and
no studies have reported the survival ability of bacteria by
simulating real human GIT conditions for bacteria (tempera-
ture, pH, salts, passage-time and speed, etc). We mimicked
human GIT conditions by a two-step incubation with simu-
lated gastric juice for 30min and bile acid for 60min, and
more than 40% of tested L. johnsonii La1 survived in these
conditions.
The presented in vitro data suggest that ingested L. johnso-
nii La1 can survive in the GIT and reach the intestine in a
viable state. To confirm these results in vivo, a randomised
double-blind placebo-controlled cross-over trial was con-
ducted. By this the effect of L. johnsonii La1 on the intestinal
microflora composition was investigated.
As seen in Table 3 and Fig. 3, increases in the number and
the ratio of Bifidobacterium in the faeces were observed after
the ingestion of the test fermented milk. It is reported that
ingestion of the fermented milk containing Bifidobacterium
and Lactobacillus increases the indigenous Bifidobacterium
(Gilliland et al. 1978; Fukushima et al. 1997; Fuller &
Gibson, 1997; Yaeshima et al. 1997). Since more than 90%
of identified Lactobacillus were L. johnsonii La1 after the
test fermented milk ingestion, the increase of Bifidobacterium
observed in the present study is possibly due to the intestinal
pH decrease induced by lactic acid or other fermented pro-
ducts produced by L. johnsonii La1. However, as the
volume of lactic acid in the faeces is too small, it is doubtful
that such a small volume of lactic acid can decrease the intes-
tinal pH. There are bacteria that utilise lactic acid such as
Megasphaera spp., Deslfolvibrio spp. and Propionibacterium
spp. (Stewart & Bryant, 1988). They might convert lactic
acid to other SCFA and induce faecal pH decrease. Although
we did not examine the changes in bacterial counts utilising
lactic acid in the present study, we did observe a tendency
of the other SCFA to increase after ingestion of the test fer-
mented milk. L. johnsonii La1 secretes non-bacteriocin anti-
microbial substances, which have a broad anti-pathogenic
spectrum (Salmonella typhimurium, Listeria monocytogenes,
Pseudomonas aeruginosa, etc), but are not effective against
Bifidobacteria and Lactobacillus (Bernet-Camard et al.
1997). Although we did not demonstrate the production of
antimicrobial substances in vivo, it might be speculated that
these antimicrobial substances also contribute to the change
in the intestinal environment advantageous for the growth of
Bifidobacterium. Intestinal pH decrease inhibits the growth
of harmful bacteria (Eklund, 1983). In accordance with this,
we observed decreases in the number and the appearance
ratio of lecithinase-positive Clostridium, which is associated
with carcinogenic enzyme production. It is also known that
ingestion of L. johnsonii La1 decreases the carcinogenic
enzymes nitroreductase and azoreductase in human subjects
(F. Rochat, unpublished results).
SCFA in the intestine, especially butyric acid, are utilised
for energy by the intestine and promote peristaltic movements
of the intestine (Yokokura et al. 1977; Young & Gibson,
1995). Poor peristalsis causes defecation frequency decrease,
so-called constipation. Chronic constipation is related to var-
ious diseases such as colon cancer. Thus, it is important to pre-
vent constipation to improve quality of life. As seen in Fig. 7,
increase in defecation frequency was observed in the subjects
Fig. 5. Effect of the fermented milk on faecal SCFA concentrations. Data are expressed as mean values (n 22), with standard deviations represented by vertical
bars. * Lactic acid significantly increased from day 0 to day 22 during the test period and during the placebo period (P,0·05). † Valeric acid significantly increased
from day 0 to day 11 during the test period (P,0·05).
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Fig. 6. Effect of the fermented milk on faecal pH. Data are expressed as
mean values (n 22), with standard deviations represented by vertical bars. *
Faecal pH was significantly decreased compared with day 0 (P,0·05).
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with mild constipation (less than seven times defecation/week
during the observation period) after the ingestion of the test
fermented milk. A tendency of increased butyric acid and
total organic acid concentration was also observed. Hence,
increased organic acids might be utilised for energy by the
intestine and promote peristaltic movements, and then increase
defecation frequency. These data suggest that the fermented
milk containing L. johnsonii La1 has beneficial effects to
improve the intestinal microflora and defecation frequency.
During the placebo period, a decrease in the number of
lecithinase-positive Clostridium number and tendency of
increased defecation frequency were observed. Although the
placebo-fermented milk does not contain L. johnsonii La1, it
contains lactose and fermented products that have intrinsic
effects to improve the intestinal microflora. It is likely that
the placebo-fermented milk used in the present study may
have impact on the intestinal microflora. However, no changes
were observed on Bifidobacterium, Lactobacillus and faecal
pH. These findings indicate that the observed improvements
of intestinal microflora and defecation frequency by the test
fermented milk are apparently stronger than those by the pla-
cebo fermented milk. According to the subjects’ question-
naires, the amounts of ingested nutrients, such as dietary
fibre, did not change so much during the study period and
the nutritional components were the same between the test
and placebo fermented milk. The only difference between
the test and placebo fermented milk is the presence of L. john-
sonii La1, suggesting that L. johnsonii La1 has an essential
role for intestinal microflora improvement.
In order to exert the beneficial effects on health, it is import-
ant for probiotics to access the intestine as a viable strain, i.e.
survive the human GIT, but no reports have shown the survi-
val ability of L. johnsonii La1 in human GIT using a strain-
specific DNA primer for L. johnsonii La1. In the present
study, we examined the survival ability of L. johnsonii La1
in the human GIT by identifying L. johnsonii La1 in the
faeces with a RAPD-PCR method (Welsh & McClelland,
1991; Johansson et al. 1995) using a specific primer for L.
johnsonii La1 (Ventura & Zink, 2002). L. johnsonii La1 was
identified in all subjects who ingested the test fermented
milk only during the test period. More than the ingested
number of L. johnsonii La1 (1 £ 109 cfu/d) was identified
from nine out of twenty-two subjects. L. johnsonii La1 was
identified within 3 d after stopping the test fermented milk.
Since the turnover cycle of IEC is 3–4 d, colonised L. johnso-
nii La1 in the intestine might disappear followed by the IEC
turnover. These results suggest that L. johnsonii La1 has an
ability to reach the intestine as a viable bacterium, and to pro-
liferate and colonise temporarily in the intestine. The fact that
L. johnsonii La1 disappeared within 4 d after stopping the test
fermented milk is also important to show the safety of L. john-
sonii La1. Thus, the probiotic properties of L. johnsonii La1 to
reach the intestine as a viable strain and colonise in the intes-
tine seems to work favourably in the improvement of the
intestinal microflora.
In conclusion, the strain-specific effect of L. johnsonii La1
to improve the intestinal microflora as a viable strain was elu-
cidated in the present study. L. johnsonii La1 is of human
origin, safe for consumption (Shu et al. 1999), adheres to
human intestinal cell lines, survives in the human GIT and
colonises temporarily in the intestine, produces antimicrobial
substances, antagonises the pathogenic bacteria, and has ben-
eficial effects on human health. Therefore, L. johnsonii La1
can be a useful tool to promote human health as a probiotic.
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